Plus Therapeutics Appoints Dr. Pius Maliakal as VP of Clinical Operations
By Daniella Parra
Plus Therapeutics (Nasdaq: PSTV) said it appointed Dr. Pius Maliakal as VP of Clinical Operations.
With over 20 years of global oncology experience, he will lead key clinical initiatives, advancing the ReSPECT-GBM and ReSPECT-LM trials for central nervous system cancers, the company said.
“Pius has a unique blend of experience in oncologic clinical development and trial operations that will make an immediate positive impact to our team,” said Marc Hedrick, M.D., President and Chief Executive Officer. “As we move our co-lead programs in glioblastoma and leptomeningeal metastases to the next clinical stages, our clinical operational team also needs to expand and advance. We are confident in Pius’ track record of clinical leadership, successful regulatory submissions, early- to late-stage trial preparation and execution with novel investigational therapeutics.”
Contact:
Editor@Executives-edge.com
